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Objective: The use of cardiopulmonary bypass in lung transplantation remains
controversial. Previous studies have concluded that cardiopulmonary bypass is
deleterious, but these studies were confounded by the inclusion of patients with
different diagnoses undergoing single- and double-lung transplantation with elective
or emergency use of bypass. The goal of this study was to determine whether
cardiopulmonary bypass has deleterious effects on lung function or clinical outcome
by analyzing the cases of patients with a single disease entity and elective use of
bypass for bilateral sequential lung transplantation.
Methods: A retrospective review of 50 patients with chronic obstructive pulmonary
disease who underwent bilateral sequential lung transplantation was performed.
Fourteen patients who underwent elective cardiopulmonary bypass for 218.3 75.4
minutes were compared to 36 control patients.
Results: After the operation, the bypass and nonbypass groups were not significantly
different with respect to median duration of mechanical ventilation (1 day vs 1 day,
P  .76), median stay in the intensive care unit (4 days vs 4 days, P  .44), median
hospital stay (15.5 days vs 16 days, P  .74), mean increase in serum creatinine
level (1.4  1.9 mg/dL vs 0.9  1.0 mg/dL, P  .33), and mean ratio of PaO2 to
fraction of inspired oxygen at 1 hour (376.6  123 vs 357.0  218, P  .75), at 24
hours (309.9  92 vs 350.6  122, P  .26), and at 48 hours (335.0  144 vs
316.2  120, P  .64). Late outcome markers compared between the bypass and
nonbypass groups were the following: 1-year percentage predicted forced expiratory
volume in 1 second (76.1% 17.0% vs 85.3% 21.7%, P .24), 30-day mortality
(7.1% vs 8.3%, P  .999), 1-year survival (85.7% vs 80.1%, P  .66), 3-year
survival (64.3% vs 58.3%, P  .70), and the prevalence of bronchiolitis obliterans
syndrome (0% vs 36.1%, P  .01).
Conclusion: Cardiopulmonary bypass appears to have no deleterious effect on early
lung function or clinical outcome. We hope that this pilot study removes some of the
unwarranted fear of the use of bypass in lung transplantation for chronic obstructive
pulmonary disease.
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The technique of bilateral sequential lungtransplantation has made the procedure ofdouble-lung replacement possible withoutthe use of cardiopulmonary bypass (CPB).1However, whether to use CPB in lung trans-plantation remains controversial. Advocates
of CPB argue that if CPB is not routinely used in the setting
of bilateral sequential lung transplantation, the first im-
planted allograft is subjected to increased ischemia-reper-
fusion injury during the implantation of the second allo-
graft. This is believed to result from the fact that the entire
cardiac output is diverted to the first implanted allograft,
resulting in increased blood flow and pressure. This hyper-
perfusion injury is believed to exacerbate the obligate isch-
emia-reperfusion injury consequent to transplantation.2-4
Clinically, this may manifest as acute lung injury and allo-
graft dysfunction. Furthermore, advocates of CPB argue
that the use of CPB in lung transplantation ensures stable
recipient hemodynamics and facilitates difficult recipient
dissection. However, the deleterious effects of CPB have
been well documented since its introduction into clinical
cardiac surgery. The proinflammatory effect appears to be
the result of the activation of cytokines, leukocytes, and the
complement cascade.5 In the setting of lung transplantation,
experimental6,7 and clinical data8,9 have suggested that CPB
itself is potentially associated with acute lung injury and
allograft dysfunction.
Previous studies have reached differing conclusions re-
garding the effect of CPB in clinical lung transplanta-
tion.8-11 However, these studies are confounded by the in-
clusion of patients for whom CPB was used on an
emergency basis, single-lung recipients in whom graft func-
tion was variably affected by disease in the remaining native
lung, and patients with several diagnoses that could inde-
pendently affect outcome. The goal of this study was to
determine whether CPB in itself has a deleterious effect on
lung allograft function and clinical outcome by analyzing
the cases of patients with a single disease entity undergoing
bilateral sequential lung transplantation with elective use of
CPB. We therefore performed a retrospective review that
selected only patients with a diagnosis of chronic obstruc-
tive pulmonary disease (COPD) undergoing bilateral se-
quential lung transplantation with or without CPB. We
hypothesized that CPB itself has minimal deleterious effect
on allograft function and clinical outcome and that previous
conclusions regarding the deleterious effects of CPB have
been biased by patients’ underlying diagnoses, the proce-
dure chosen, and the circumstances in which CPB was used.
Methods
Patient Population
Between November 1991 and September 2000, a total of 252 adult
lung transplantations were performed at the Hospital of the Uni-
versity of Pennsylvania. Of these patients, 137 patients with the
diagnosis of COPD related to emphysema and 1-antitrypsin de-
ficiency underwent either single-lung (n  85) or double-lung
transplantation (n  52). The indication for lung transplantation
was severely compromised pulmonary function with a forced
expiratory volume in 1 second (FEV1) less than 20% of predicted.
In the setting of single-lung transplantation, it is difficult to ac-
count for the effects of the remaining diseased, native lung on the
recipient’s pulmonary function and clinical outcome. Moreover,
issues of differential blood flow and airflow to the pulmonary
allografts make the assessment of graft function difficult to inter-
pret. Therefore recipients undergoing bilateral sequential lung
transplantation without the use of CPB (n  36) were compared
with recipients undergoing bilateral sequential lung transplantation
with the elective use of CPB (n  14). The decision to use CPB to
provide controlled pulmonary reperfusion pressure and flow to the
newly implanted allograft during implantation of the second allo-
graft was made before recipient pneumonectomy. Historically, our
group has been using CPB for any single- or double-lung recipient
with mean pulmonary artery pressure of 40 mm Hg or more on
single-lung ventilation with maximum medical support (PCO2
25-30 mm Hg, inhaled nitric oxide at 40 ppm, intravenous alpros-
tadil at the maximum tolerable dose keeping mean arterial pressure
60 mm Hg, and isoproterenol at the maximum tolerable dose
keeping the heart rate 110 beats/min). According to the operative
notes and anesthesia records, in no case did acute hemodynamic
instability or oxygenation desaturation occur intraoperatively after
the implantation and reperfusion of the first allografts, necessitat-
ing the emergency use of CPB. CPB was instituted before implan-
tation of both lungs in 8 cases and after implantation of the first
allografts in 6 cases. Two patients who did require emergency
institution of CPB as a result of hemodynamic instability were
excluded from this study, resulting in a total of 50 patients in this
analysis. No other patients were excluded. One of these patients
had immediate, hyperacute lung rejection, resulting in cardiopul-
monary instability, cardiopulmonary arrest, and death. This patient
had a positive (100% cytotoxicity) retrospective crossmatch and
had pulmonary histologic and immunohistochemical (complement
and antibody deposition) evidence of hyperacute rejection. The
other patient displayed significant hemodynamic instability and
pulmonary hypertension during the implantation of the second
allograft while on single-lung ventilation with the newly implanted
first allograft.
Recipient demographic characteristics are listed in Table 1.
Baseline pulmonary function tests were performed for all patients
before transplantation as part of the preoperative workup. Ischemia
time was defined as the interval between crossclamping of the
donor aorta and reperfusion of the transplanted lungs. Ischemia
times for both lungs were individually recorded.
Assessment of Allograft Function
Assessment of early allograft function was made by measuring the
following markers. Requirement for mechanical ventilation was
reviewed and expressed as the median duration of intubation in
days. Chest radiographic reports at approximately 1, 24, and 48
hours after transplantation were obtained, since chest radiographic
evidence of infiltration has been suggested as a possible clinical
marker of acute lung injury. A quantitative chest radiographic
infiltrate score was assigned to each individual lung on the basis of
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the official radiologic report in the following manner: 0, normal; 1,
perihilar infiltrate or infiltrate localized to a limited lung field; 2,
mild diffuse infiltrate or edema; 3, moderate diffuse infiltrate; and
4, severe diffuse infiltrate. The difference in infiltrate scores be-
tween the first and second allograft implanted was used as one
assessment of whether CPB protects the first allograft implanted
from hyperperfusion injury. Furthermore, the number of patients,
in whom the first allograft infiltrate score was at least 2 grades
higher than the second allograft score was determined. Arterial
blood gas (ABG) values obtained at approximately 1, 24, and 48
hours after transplantation were reviewed to calculate the PaO2 to
fraction inspired oxygen ratio (PaO2/FIO2). The 1-hour ABG read-
ing was the first ABG assessment obtained on arrival in the
intensive care unit (ICU). Pulmonary function tests (percentages of
predicted forced vital capacity and FEV1) at 1 year after trans-
plantation were reviewed to assess the intermediate-term allograft
function.
Clinical Outcome
ICU stay and hospital stay in days after transplantation were
reviewed. The change in postoperative renal function was analyzed
by reviewing the baseline and the peak serum creatinine levels
attained during the hospital course. The mean increase in serum
creatinine level (peak minus baseline) was calculated. Patient
records were also reviewed for bronchial anastomotic complica-
tions and the prevalence of bronchiolitis obliterans syndrome
(BOS), as defined by the International Society for Heart and Lung
Transplantation.12 Transfusion requirements in terms of packed
red blood cells, fresh-frozen plasma, and platelets were compared
by reviewing blood bank records. The 30-day mortality and 1-year
and 3-year survivals were compared to examine the short- and
intermediate-term clinical outcomes.
Statistical Analysis
Inspection of each outcome measure was conducted to determine
the nature of its distribution. The choice of statistical model was
dependent on each outcome distribution. For measures that ap-
peared to be normally distributed or through a transformation were
normally distributed, analysis of variance was used. For measures
for which transformation did not lead to a normal distribution,
alternate statistical models were implemented. Analysis of vari-
ance was used to compare the age of the recipients, preoperative
and postoperative pulmonary function tests, PaO2/FIO2 ratio, in-
crease in serum creatinine level, and ischemic times of the allo-
grafts. To adjust for surgeon variability, the surgeons were fac-
tored as covariates (analysis of covariance) only when analyzing
ischemic times of the allografts. The cumulative logit model was
used to evaluate the chest radiographic infiltrate scores. Because of
their count nature, Poisson regression was used to evaluate ICU
and hospital stays, mechanical ventilation requirement, and trans-
fusion requirements (packed red blood cells, fresh-frozen plasma,
platelets). Logistic regression was used to evaluate the 30-day
mortality and 1- and 3-year survivals. In addition, Kaplan-Meier
analysis (Wilcoxon test) was performed on the entire population
and a subset of the non-CPB control patients (with transplantation
between 1996 and 2000) to address the difference in the operation
dates between the two groups for the survival analysis and to
account for the heavy censoring. The Fisher exact test was used for
small samples (30-day mortality). Bronchial anastomotic compli-
cation rate and the prevalence of BOS were also analyzed with the
Fisher exact test.
Results
Recipient Demographic Data
The mean duration of CPB was 218.3  75.4 minutes. As
stated previously, the decision to use CPB to provide con-
trolled pulmonary reperfusion pressure and flow to the
newly implanted allografts was made before recipient pneu-
monectomy. The recipient demographic characteristics are
shown in Table 1. No significant differences in recipients’
age (P  .13), sex (P  .93), preoperative pulmonary
function tests (percentage of predicted forced vital capacity
P  .94, percentage of predicted FEV1 P  .94), and
allograft ischemic time (first lung P .11, second lung P
.40) were seen. These findings confirmed the comparability
of the populations of patients for this study.
Postoperative Allograft Function
There was no significant difference in postoperative me-
chanical ventilation requirement (median duration of intu-
bation in days) between the CPB group (1 day) and the
non-CPB group (1 day, P  .76; Figure 1). The mean
TABLE 1. Preoperative characteristics
Characteristic Non-CPB CPB P value
Age (y, mean  SD) 49.9 8.5 53.8 6.1 .13
Gender (% male) 62.9 64.3 .93
Proportion of predicted forced
vital capacity (%, mean  SD)
57.6 18.4 57.1 14.3 .94
Proportion of predicted FEV1
(%, mean  SD)
20.1 6.4 20.3 6.1 .94
Ischemia time (min, mean  SD)
For 1st allograft 205.1 50.1 254.7 55.2 0.11*
For 2nd allograft 322.3 59.4 384.6 79.3 .4*
P values were calculated by analysis of variance.
*Adjusted for surgeons as covariates in the analyses.
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differences in chest radiographic infiltrate scores between
the first and second lungs implanted were compared at three
time points after transplantation (1, 24, and 48 hours). At 1
hour after transplantation, the mean (SD) differences in
infiltrate score between the first and second allografts were
0.4  0.5 in the CPB group and 0.2  0.8 (P  .19) in the
non-CPB group. At 24 hours, the differences in infiltrate
scores were 0.3  0.5 and 0.2  0.6 in the CPB and
non-CPB groups, respectively (P  .65). At 48 hours, the
differences in infiltrate score were 0.1  0.4 in the CPB
group and 0.1  0.4 in the non-CPB group (P  .99). None
of the 14 patients in the CPB group had an infiltrate score in
the first lung implanted that was 2 grades or more higher
than in the second lung implanted at 1 hour, whereas 3
patients in the non-CPB group (n  36) had an infiltrate
score in the first lung implanted that was 2 grades or more
higher than that in the second lung implanted at 1 hour. This
trend was not statistically significant (P  .55). The ABG
values were examined to calculate the PaO2/FIO2 ratios after
transplantation at intervals of 1, 24, and 48 hours (Figure 2).
Immediately on arrival in the ICU, the mean PaO2/FIO2 ratio
in the CPB group was 376.6 123 and that in the non-CPB
group was 357.0  218 (P  .75). These were recorded as
the 1-hour PaO2/FIO2 ratios, because the ABG values were in
all cases obtained at least 1 hour after reperfusion of the
allografts. At 24 hours, the PaO2/FIO2 ratios were 309.9 92
and 350.6  122 in the CPB and non-CPB groups, respec-
tively (P .26). At 48 hours, the PaO2/FIO2 ratio in the CPB
group was 335.0  144 and that in the non-CPB group was
316.2  120 (P  .64). Because this was not a prospective
study, ABG values were not obtained at exactly 24 and 48
hours. The closest ABG determination to the reported in-
terval was therefore used. At 1 year after transplantation,
pulmonary function tests were performed to assess the in-
termediate-term allograft function (Figure 3). There were no
significant differences between the two groups in the per-
centage of expected FEV1 (CPB 76.1%  17.0%, non-CPB
85.3%  21.7%, P  .24).
Clinical Outcome
The median stay in the ICU was the same for the CPB and
non-CPB groups (4 days, P  .44, Figure 4). Similarly,
there was no difference in the median duration of hospital
stay (CPB 15.5 days, non-CPB 16 days, P  .74, Figure 4).
The mean perioperative increases in serum creatinine level
(peak minus baseline level) were 1.4  1.9 mg/dL and
0.9  1.0 mg/dL (P  .33) in the CPB and non-CPB
groups, respectively. Bronchial anastomotic stenosis requir-
ing stent placement or dilatation occurred in 1 of 14 patients
(7.1%) in the CPB group and in 4 of 36 patients (11.1%) in
the non-CPB group (P  .999). Bronchial dehiscence did
Figure 2. Postoperative PaO2/FIO2 ratio in CPB group (white bars)
and non-CPB group (black bars). Bar heights represent mean;
error bars represent SD. Asterisk indicates P  .75; double
asterisk indicates P  .26; triple asterisk indicates P  .64.
Figure 1. Requirement for mechanical ventilation after lung trans-
plantation in CPB and non-CPB (NCPB) groups. Asterisk indicates
P  .76.
Figure 3. Pulmonary function (forced expiratory volume in 1 sec-
ond, FEV1) before (Pre-Txp) and 1 year after lung transplantation
in CPB group (white bars) and non-CPB group (black bars). Bar
heights represent mean; error bars represent SD. Asterisk indi-
cates P  .94; double asterisk indicates P  .24.
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not occur in either group. None of the 14 patients in the CPB
group showed clinical evidence of BOS, whereas 13 of 36
patients (36.1%) in the non-CPB group had clinical evi-
dence of decline in pulmonary function consistent with BOS
(P  .01). To correct for potential differences in the time
allowed for development of BOS, a subset (n  13) of
patients in the non-CPB group who underwent transplanta-
tion between 1996 and 2000 was analyzed. The prevalence
of BOS in this group was 4 of 13 (30.8%), which was
significantly different from the 0% prevalence of BOS in the
14 patients in the CPB group (P  .047). However, blood
product requirements were higher in the CPB group (packed
red blood cells 6.5 4.1 units vs 2.1 1.7 units, P .001,
platelets 1.4  1.4 units vs 0.1  0.3 units, P  .001,
fresh-frozen plasma 11.0  7.7 units vs 0.3  0.8 units,
P  .001; Figure 5).
Survival
The effects of CPB on short- and intermediate-term survival
were examined (Table 2). When the Fisher exact test and
logistic regression were used to analyze the entire study
period, the 30-day mortalities were similar in the CPB and
non-CPB groups (7.1% vs 8.3%, P  1.0). Similarly, inter-
mediate-term survival data were also not significantly dif-
ferent between the two groups. The 1-year and 3-year sur-
vivals in the CPB group (85.7% and 64.3%, respectively)
were comparable to those in the non-CPB group (80.1%,
P  .66, and 58.3%, P  .70). A Kaplan-Meier analysis
(Wilcoxon test) of the entire study period also demonstrated
that the median survival times were not significantly differ-
ent between the CPB group (1407 days) and the non-CPB
group (2591 days, P  .86). A Kaplan-Meier analysis
(Wilcoxon test) of patients who underwent transplantation
between 1996 and 2000 also demonstrated that there was no
difference in survival between the CPB and non-CPB
groups (P  .73). This subset analysis was performed to
address the limitations of the Kaplan-Meier method, which
biases in favor of patients with longer follow-ups in the
setting of a small sample size and significant censoring of
data. This subset of patients who underwent transplantation
between 1996 and 2000 was also used to address the learn-
ing curve in our experience in lung transplantation. In this
subset of patients, the Fisher exact test and logistic regres-
sion model again demonstrated no difference in the 30-day
mortality (CPB 7.1% vs non-CPB 15.3%, P  .60) and the
1-year survival (CPB 85.7% vs non-CPB 69.2%, P  .30).
The 3-year survival was 64.3% in the CPB group and 23.1%
in the non-CPB group (P  .03). The causes of death are
listed in Table 3.
Discussion
The introduction of bilateral sequential lung transplantation
has provided surgeons the ability to perform double-lung
transplantation without the use of CPB.1 Since inception of
the procedure, the use of CPB in lung transplantation has
remained a much debated topic. Experimental and clinical
investigators have reached differing conclusions regarding
the effects of CPB in lung transplantation. Our review of the
current literature found that the retrospective clinical studies
to date are weakened by inclusion of patients with different
Figure 4. Lengths of ICU and hospital stays after lung transplan-
tation in CPB group (white bars) and non-CPB group (black bars).
Asterisk indicates P  .44; double asterisk indicates P  .74.
Figure 5. Postoperative blood product requirements in CPB group
(white bars) and non-CPB group (black bars). Bar heights repre-
sent mean; error bars represent SD. Asterisk indicates P < .001.
PRBC, Packed red blood cells; PLT, platelets; FFP, fresh-frozen
plasma.
TABLE 2. Survivals
Non-CPB CPB P value
30-d mortality 8.3 7.1 .999*
1-y survival 80.1 85.7 .66†
3-y survival 58.3 64.3 .70†
*By 2-sided Fisher exact test.
†By logistic regression analysis.
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diagnoses, both single- and double-lung transplants, and
both elective and emergency use of CPB. These confound-
ing variables prevent clear assessment of whether CPB is in
fact deleterious. Patients with different diagnoses represent
a heterogeneous population with contrasting medical con-
ditions and background. In the setting of single-lung trans-
plantation, the remaining native lung can have a significant
effect on short-term and long-term posttransplantation pul-
monary function. Circumstances involving the use of CPB
can also have effects on clinical outcome. Emergency use of
CPB resulting from hemodynamic instability or oxygen
desaturation may be a surrogate for patients with poor
pulmonary reserve, thus introducing patient selection bias.
Moreover, borderline or frank shock before institution of
CPB clearly has multisystemic adverse effects on organ
function. We believe that the current opinion in the litera-
ture regarding the deleterious effect of CPB in lung trans-
plantation may not be entirely warranted. The goal of this
study was to determine whether CPB is deleterious by
conducting a study devoid of the bias potentially introduced
by these factors. To achieve this, our study examined only
patients with diagnosis of COPD undergoing bilateral se-
quential lung transplantation with or without elective CPB.
Unlike many centers, we have a sizable number of patients
with COPD and emphysema undergoing bilateral sequential
lung transplantation because of a large number of younger
patients referred with 1-antitrypsin disease. We have pre-
viously reported excellent results with this approach.13,14
Our study found that CPB was not associated with any
deleterious effects on lung function, although we recognize
that the small size of the study limits our ability to detect
subtle differences. In terms of allograft function, the CPB
group was not significantly different in duration of intuba-
tion, PaO2/FIO2 ratio, and 1-year pulmonary function test
results. We also compared the chest radiographic infiltrate
scores between the first and second lung implanted, recog-
nizing that this is an unproven marker of asymmetric injury.
The difference between the first and the second lung im-
planted infiltrate scores was not significantly different be-
tween the CPB group the non-CPB group. This assessment
was not particularly sensitive, however, because our method
of chest radiographic assessment was to assign grades on
the basis of the official radiology report. It is therefore not
surprising that mean infiltrate scores were not sensitive
enough to demonstrate a difference. However, when we
looked at the percentage of patients with a marked differ-
ence in infiltrate score between the two lungs (at least a
2-grade difference), we found that 3 of 36 patients in the
non-CPB group had radiologic evidence of significant “first
lung” injury. In contrast, none of the 14 patients in the CPB
group had evidence of similarly severe injury. Although this
trend was not statistically significant, it shows that CPB did
not have a major deleterious effect and even suggests that
CPB may be beneficial. To prove that hypothesis would
clearly require a much larger study involving blinded, pro-
spective scoring of chest radiographs. In terms of clinical
outcome, the CPB group also did not exhibit significant
differences in ICU stay, hospital stay, renal function, bron-
chial anastomotic complications, 30-day mortality, and
1-year and 3-year survivals. However, we did find that the
prevalence of BOS was lower in the CPB group (0%) than
in the non-CPB group (36.1%). Although this finding was
statistically significant, we suspect that it may not reflect a
true biologic phenomenon, because it is well established
that the prevalence of BOS among heart-lung transplant
recipients, who all require CPB, is no lower than in lung
transplant recipients, some of whom do not undergo CPB.
We did find a significant increase in blood transfusion
requirements in the CPB group.
Approximately two thirds of the transplants performed in
the non-CPB group occurred between 1993 and 1996. This
is in contrast to the CPB group, in which all transplantation
procedures were performed from 1996 to 2000. This raises
the possibility that our results merely reflect a learning
curve. Moreover, the differences in the starting dates be-
tween the two groups introduce heavily censored data into
the Kaplan-Meier analysis. This is particularly relevant be-
cause our sample size was small. To address these issues,
we analyzed a subset of patients who underwent lung trans-
plantation between the period of 1996 to 2000 by means of
logistic regression analysis. We found no statistically sig-
nificant differences between the CPB (n  14) and the
non-CPB (n  13) groups in the same parameters analyzed
for the entire study period. However, we did see a better
3-year survival (64.3%) in the CPB group than in the
non-CPB group (23.1%, P  .03). The impact of the learn-
ing curve for transplantation on patient clinical outcome is
a valid concern, but the analysis of the subset of patients in
the later group (1996 to 2000) suggested that it did not have
a significant effect in our experience. To address the issue of
heavily censored data, Kaplan-Meier analysis with the Wil-
coxon test was performed. The analysis of the entire popu-
TABLE 3. Causes of death
Non-CPB CPB
BOS 3 0
Primary graft failure 2 1
Posttransplantation lymphoproliferative disease 1 1
Pneumonia 1 1
Myocardial infarction 1 0
Colitis or perforation 2 0
Chronic renal failure and congestive heart
failure
0 1
Lung malignancy 1 0
Guillain-Barre´ syndrome 1 0
Data represent numbers of patients.
Cardiothoracic Transplantation Szeto et al
246 The Journal of Thoracic and Cardiovascular Surgery ● August 2002
TX
lation as well as the subset of contemporaneous non-CPB
control patients showed survival to be equivalent between
the CPB and non-CPB groups. Survival appeared to be
similar between the two groups once heavy censoring was
accounted for, suggesting the significance of censoring in
this sample size. The efficiency of the results from the
logistic regression analysis was not impaired by the heavy
censoring, further supporting its use as the optimal method
for comparing the 30-day, 1-year, and 3-year survivals.
The theory that CPB may control reperfusion pressure
and flow during implantation of second lung, thereby re-
ducing overall ischemia-reperfusion injury to the first im-
planted allograft, has stimulated much debate and investi-
gation. Without CPB, the diversion of the entire cardiac
output to the first implanted lung can result in pulmonary
overcirculation, which often translates into allograft dys-
function. In cardiac surgery as well as orthotopic heart
transplantation, the benefits of controlled reperfusion with
the use of CPB are well established both experimentally15
and clinically.16,17 The concerns of sudden reperfusion in-
jury appear valid for lung transplantation. Experimental
data have shown that increased flow and pressure may lead
to lung dysfunction. In a canine model, Fullerton and asso-
ciates3 demonstrated that chronically increased pulmonary
blood flow after creating a 3:1 left-to-right shunt resulted in
dysfunctional pulmonary vasorelaxation. In an ex vivo rab-
bit model, DeLima and associates2 demonstrated that rabbit
lungs receiving high-flow reperfusion resulted in an in-
crease in pulmonary vascular resistance, a decrease in dy-
namic airway compliance, and an increased wet/dry weight
ratio. Furthermore, experimental and clinical studies have
demonstrated the benefits of controlled reperfusion in lung
transplantation. In an ex vivo rat lung model, Hopkinson
and associates4 demonstrated that controlled pressure reper-
fusion of pulmonary grafts resulted in improved pulmonary
function. In an in vivo porcine lung transplantation model,
Halldorsson and associates18-20 demonstrated that reperfu-
sion injury was avoided by controlling the composition
(modified solution, leukocyte filter) and the conditions
(pressure and rate) of the reperfusate. Recently, Lick and
associates21 reported a clinical series of 5 patients undergo-
ing lung transplant procedures with a modification of the
technique described by Halldorsson and associates.18
Controlled reperfusion was achieved by passing the
reperfusate through a leukocyte filter and into the transplant
pulmonary artery at a controlled rate (200 mL/min) and
pressure (20 mm Hg). The investigators reported excel-
lent functional results in these patients compared with his-
torical control patients at their institution.21
In addition to our review, other clinical studies have also
added evidence that CPB is not deleterious to clinical out-
come after lung transplantation. In a retrospective review of
162 patients, Triantafillou and associates11 found no differ-
ence between the CPB and non-CPB groups in terms of time
until extubation, time spent in the ICU, and time required to
reach a PO2 on room air greater than 60 mm Hg. In a review
of the Cleveland Clinic experience, Hlozek and associates10
found no difference between the CPB and non-CPB groups
in terms of patient survival, initial PaO2/FIO2, and length of
ICU stay. However, they did find a significant difference in
the duration of intubation and blood transfusion require-
ment.
Opponents of CPB argue that CPB elicits a “whole-
body” inflammatory response that may be detrimental to the
pulmonary allograft. It has been well documented that CPB
activates leukocytes22,23 and the complement pathway24 and
increases the release of cytokines and interleukins.25,26 The
introduction of activated blood components may result in
acute lung injury. Fullerton and associates7 demonstrated in
a canine lung transplantation model that CPB exaggerates
pulmonary vasomotor dysfunction in the transplanted lung,
which results in a higher pulmonary vascular resistance.
Clinical studies have also suggested the CPB may have a
deleterious effect on patient morbidity and mortality. In a
retrospective review of 100 patients undergoing lung trans-
plantation, Aeba and associates9 found that patients in the
CPB group had significantly worse arterial-alveolar PO2
ratio, more severe pulmonary infiltrates on chest radio-
graphs, longer duration of intubation, and worse survival at
1 month after operation than did the non-CPB group. Sim-
ilarly, in a retrospective review of 94 double-lung transplan-
tations, Gammie and associates8 found that CPB was asso-
ciated with more perioperative transfusion requirements,
lower arterial-alveolar PO2 ratio, more severe pulmonary
infiltrates, and longer duration of intubation. However, the
30-day mortality and the 1-year survival were not signifi-
cantly different between groups.
Even though our data suggest that CPB has no deleteri-
ous effect, we understand that our study has some limita-
tions. First, we cannot conclude that CPB is beneficial on
the basis of our data. However, the goal of this study was to
test the hypothesis that CPB has no deleterious effects on
graft function and therefore clinical outcome in lung trans-
plantation, once confounding factors are eliminated. We
believe that controlled reperfusion is an important concept
and hope that this study will raise significant questions
about the adverse effects of CPB in lung transplantation. We
believe that prospective, randomized studies to assess the
role of controlled reperfusion in minimizing ischemic-reper-
fusion injury are warranted. Second, for a comparison of a
homogeneous population undergoing the same procedure,
the number of patients in the study was small. We realize
that a type II error, or failure to reject a null hypothesis
when it is false, is possible in this study. Our study does not
have the power to definitively rule out any deleterious effect
of CPB. We have performed power calculations for this
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study’s findings, and for an  of .05 and a power of 80%, we
would have needed 26 patients per group to detect a large
effect size, 65 patients per group to detect a medium effect
size, and 390 patients per group to detect a small effect size.
Third, we realize that this is a retrospective review, and the
decision to use CPB electively is biased by the individual
surgeon’s preference. Finally, patients were not randomly
assigned to study the effect of CPB. As previously dis-
cussed, a prospective, randomized study with a significant
sample size would be required to definitely conclude that
CPB does not deleteriously affect lung function or clinical
outcome.
The technical aspects of lung transplantation are chal-
lenging and continue to evolve at our institution. Our cur-
rent practice is to use CPB in the setting of pulmonary
hypertension (mean PaO2 40 mm Hg) on maximal support
(PCO2 25-30 mm Hg, inhaled nitric oxide at 40 ppm, iso-
proterenol at the maximum tolerable dose keeping heart rate
110 beats/min, and alprostadil at the maximum tolerable
dose keeping mean arterial pressure 60 mm Hg). Our prac-
tice in the setting of bilateral sequential lung transplantation
in the absence of pulmonary hypertension continues to
evolve. Currently we favor routine elective use of CPB
during the implantation of the second pulmonary allograft to
control perfusion pressure in the first lung, to eliminate
hemodynamic instability or hypoxia during the procedure,
and to aid in exposure of the left hilar structures. Although
there is evidence suggesting that the use of heparin-bonded
circuits and leukocyte filtration may provide additional ben-
efit, we do not currently use this approach in our program.
Whether controlled reperfusion is protective against isch-
emia-reperfusion injury is still unknown. However, our
study suggests that there is minimal deleterious effect of
CPB on lung transplantation used electively in the specific
setting of bilateral sequential lung transplantation for pa-
tients with COPD. Even though CPB resulted in a higher
transfusion requirement, it did not adversely affect allograft
function and clinical outcome. Although we are not advo-
cating routine use of CPB for either single- or double-lung
transplantation procedures, we hope that this study will
remove some of the unwarranted fear of the use of CPB in
lung transplantation for COPD.
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